What is the current Preimplantation Genetics Diagnosis (PGD) market size?

The current PGD market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the PGD market?

The PGD market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the PGD market?

Advances in genetic testing and increasing awareness of genetic disorders drive the PGD market.

What are the challenges facing the PGD market?

High costs and regulatory hurdles are significant challenges in the PGD market.

Which regions are leaders in the PGD market?

North America and Europe are the leading regions in the PGD market.

Who are the top companies in the PGD market?

Illumina and Thermo Fisher Scientific are top companies in the PGD market.

What future opportunities exist in the PGD market?

The future outlook for PGD includes increased adoption in emerging economies.

How does technology impact the PGD market?

Advances in next-generation sequencing technology are transforming the PGD market.

What is the current regulatory landscape for PGD?

The regulatory landscape for PGD varies by country, with some having strict regulations.

How will the PGD market evolve in the next 5 years?

The PGD market will evolve with increased use of AI and machine learning for genetic analysis.

Preimplantation Genetics Diagnosis (PGD) Growth Drivers & Forecast Analysis 2033

Preimplantation Genetics Diagnosis (PGD) by Application (Hospitals, Clinics, Others), by Types (Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, X-Linked Diseases, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Preimplantation Genetics Diagnosis (PGD) Market Overview

The Preimplantation Genetics Diagnosis (PGD) market refers to the industry involved in the genetic testing of embryos prior to implantation during in vitro fertilization (IVF) procedures. As the PGD market size is estimated to be around $4.2 billion in 2025, its growth outlook and market forecast are of significant interest to stakeholders. The PGD market forecast indicates a promising industry expansion, driven by increasing demand for genetic testing and advancing technologies. With a compound annual growth rate (CAGR) expected to be around 10%, the market is poised for substantial growth. Key forces shaping the industry include technology shifts, regulatory frameworks, and changing consumer behavior, with the largest region being North America and the fastest-growing region being the Asia-Pacific.

Loading chart…

The growth of the PGD market is driven by factors such as the increasing prevalence of genetic disorders, advancements in genetic testing technologies, and growing awareness about the benefits of PGD. The market is expected to experience significant growth in the forecast period, with the largest region being North America, driven by the high adoption rate of PGD in the US. The fastest-growing region is the Asia-Pacific, driven by the growing demand for PGD in countries such as China and India. Overall, the PGD market is expected to experience substantial growth, driven by technological advancements, increasing demand, and expanding applications.

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	27.40 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Natera, Inc.; PerkinElmer; Illumina; F. Hoffmann-La Roche; Thermo Fisher Scientific; Laboratory Corporation of America Holdings; Agilent Technologies; Quest Diagnostics Incorporated; Cooper Surgical; Beijing Genomics Institute (BGI); Genea Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Preimplantation Genetics Diagnosis (PGD) market is poised for significant growth, driven by increasing awareness and adoption of genetic testing technologies. The Preimplantation Genetics Diagnosis (PGD) market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in genetic sequencing technologies have improved the accuracy and efficiency of PGD procedures, making them more accessible to a wider range of patients.

Government initiatives and funding for genetic research have supported the development of new PGD technologies and treatments, driving market growth.

Restraints2 items

High costs associated with PGD procedures and limited insurance coverage have restricted access to these services, hindering market growth.

Stringent regulatory frameworks and ethical concerns surrounding genetic testing have slowed the adoption of PGD technologies in some regions.

Opportunities2 items

The increasing prevalence of genetic disorders and rising demand for personalized medicine have created new opportunities for PGD market players to develop targeted treatments and services.

Emerging markets in Asia-Pacific and Latin America offer significant growth potential for PGD market vendors, driven by improving healthcare infrastructure and growing awareness of genetic testing.

Challenges2 items

The Preimplantation Genetics Diagnosis (PGD) market faces intense competition, with numerous players offering similar services, making it challenging for companies to differentiate themselves and maintain market share.

The need for specialized training and expertise in PGD procedures has created a shortage of skilled professionals, limiting the ability of market players to expand their services and meet growing demand.

Market Segmentation

Loading chart…

The Application segment of the Preimplantation Genetics Diagnosis (PGD) market refers to the various uses of PGD in the field of genetics and reproductive medicine. This segment contributes significantly to the overall PGD market size, as it encompasses a range of applications including anomaly detection, genetic disorder diagnosis, and family balancing. Understanding the Preimplantation Genetics Diagnosis (PGD) segmentation is crucial for market players to identify opportunities and develop targeted strategies.

The Types segment of the PGD market is further divided into subtypes, including [object Object] and [object Object]. These subtypes represent different approaches to PGD, such as fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS). Each subtype has its own set of advantages and limitations, and contributes to the overall PGD market size. Analyzing the market taxonomy of the PGD industry is essential to understand the dynamics of this segment and identify areas of growth.

Preimplantation Genetics Diagnosis (PGD) Segmentation Breakdown12 items

Application

Hospitals

Clinics

Others

Types

Gender Selection

Chromosomal Abnormalities

Single Gene Disorders

HLA Typing

Aneuploidy

X-Linked Diseases

Others

Regional Insights

Loading chart…

The Preimplantation Genetics Diagnosis (PGD) market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of PGD technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, demographics and ecosystem maturity; for Europe, infrastructure and regulatory frameworks; for Asia Pacific, government initiatives and rising awareness; for Latin America, expanding healthcare access and growing demand; and for Middle East & Africa, increasing investments and improving healthcare infrastructure.

The regional forecast indicates that the PGD market will witness significant growth in the Asia Pacific region, driven by the large population, increasing awareness about genetic disorders, and improving economic conditions. In contrast, the Middle East & Africa region is expected to experience relatively slower growth due to limited access to healthcare services and lower awareness about PGD technologies.

Competitive Landscape

The Preimplantation Genetics Diagnosis (PGD) market is moderately consolidated, with a mix of global players and local companies competing on factors like pricing, distribution, and product innovation. The Preimplantation Genetics Diagnosis (PGD) competitive landscape is driven by key levers such as regulatory approvals, certifications, and strategic partnerships. Global players have a significant presence, but local companies are also gaining traction, particularly in emerging markets.

Companies in the PGD market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, and R&D investments. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must adapt to changing market dynamics and evolving customer needs.

Abbott Laboratories: regional expansion

Natera, Inc.: innovation pipeline

PerkinElmer: premium pricing

Illumina: OEM tie-ups

F. Hoffmann-La Roche: local manufacturing

Thermo Fisher Scientific: vertical integration

Key Preimplantation Genetics Diagnosis (PGD) Companies12 items

Abbott Laboratories

Natera, Inc.

PerkinElmer

Illumina

F. Hoffmann-La Roche

Thermo Fisher Scientific

Laboratory Corporation of America Holdings

Agilent Technologies

Quest Diagnostics Incorporated

Cooper Surgical

Beijing Genomics Institute (BGI)

Genea Limited

Market Ecosystem

The Preimplantation Genetics Diagnosis (PGD) ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created through the development and supply of genetic testing technologies, integration of these technologies into clinical workflows, and delivery of PGD services to patients. The ecosystem's boundaries are defined by the interactions between these segments, where technology providers supply genetic testing products, integrators develop and implement PGD protocols, and channels deliver these services to end users.

Technology providers — supply genetic testing products

System integrators — develop and implement PGD protocols

Distributors — deliver PGD products to clinical settings

Service providers — offer PGD testing and counseling services

End users — patients seeking genetic testing and counseling

Regulators — establish standards and approvals for PGD technologies

Data/analytics providers — support PGD data interpretation and analysis

In the Preimplantation Genetics Diagnosis (PGD) ecosystem, control points are primarily held by regulators, who influence adoption through standards and approvals, and technology providers, who drive innovation and supply of genetic testing products. Dependency risks arise from input constraints, such as access to high-quality genetic samples, and standards, which can vary by region. Switching costs and partnerships are also critical, as clinics and patients may be locked into specific PGD technologies or services, and interoperability requirements can impact the integration of different technologies. A thorough value chain analysis is essential to understanding these dynamics and how they impact the PGD ecosystem.

Recent Industry Insights

The Preimplantation Genetics Diagnosis (PGD) industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as the collaboration between genetic testing companies and fertility clinics, to enhance the accessibility of PGD services. Additionally, there have been strategic mergers and acquisitions, including the acquisition of smaller genetic testing firms by larger corporations, to expand their service offerings and strengthen their market presence.

Furthermore, several product launches have taken place, featuring advanced genetic testing technologies that improve the accuracy and efficiency of PGD procedures. Regulatory changes have also been implemented, with updated guidelines for the use of PGD in certain countries, reflecting a shift in consumer and enterprise trends towards increased adoption of genetic testing services. Funding rounds and expansions have been secured by key players in the industry, enabling them to invest in research and development and drive growth in the Preimplantation Genetics Diagnosis (PGD) market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Preimplantation Genetics Diagnosis (PGD) market outlook. The market attractiveness is high due to increasing demand for genetic testing and advancements in technology. Competitive intensity is moderate, with key players investing in research and development to improve PGD techniques. The long-term outlook is positive, driven by growing awareness of genetic disorders and the need for early diagnosis.

The innovation landscape is dynamic, with ongoing research focused on improving the accuracy and efficiency of PGD procedures. Demand-supply balance is stable, with increasing demand met by expanding services from existing providers. However, key risk factors include regulatory changes and public perception of genetic testing. Overall, the Preimplantation Genetics Diagnosis (PGD) market outlook is favorable, with opportunities for growth and innovation in the coming years.

11 items

1. Executive Summary

2. Preimplantation Genetics Diagnosis (PGD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Preimplantation Genetics Diagnosis (PGD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Preimplantation Genetics Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global Preimplantation Genetics Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Gender Selection

6.2.2. Chromosomal Abnormalities

6.2.3. Single Gene Disorders

6.2.4. HLA Typing

6.2.5. Aneuploidy

6.2.6. X-Linked Diseases

6.2.7. Others

6.3. Global Preimplantation Genetics Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Preimplantation Genetics Diagnosis (PGD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Preimplantation Genetics Diagnosis (PGD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Preimplantation Genetics Diagnosis (PGD) Market Competition by Key Manufacturers

8.1. Global Preimplantation Genetics Diagnosis (PGD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Preimplantation Genetics Diagnosis (PGD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Natera, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. PerkinElmer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. F. Hoffmann-La Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Laboratory Corporation of America Holdings

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Agilent Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quest Diagnostics Incorporated

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Cooper Surgical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Beijing Genomics Institute (BGI)

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Genea Limited

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Preimplantation Genetics Diagnosis (PGD) Market

Figure 4: Global Preimplantation Genetics Diagnosis (PGD) Market: Drivers

Figure 5: Global Preimplantation Genetics Diagnosis (PGD) Market: Challenges

Figure 6: Global Preimplantation Genetics Diagnosis (PGD) Market: Trends

Figure 7: Global Preimplantation Genetics Diagnosis (PGD) Market: Opportunity

Figure 8: Global Preimplantation Genetics Diagnosis (PGD) Market: Restraint

Figure 9: Global Preimplantation Genetics Diagnosis (PGD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Preimplantation Genetics Diagnosis (PGD) Market Value (USD Million) By Region

Figure 15: Global Preimplantation Genetics Diagnosis (PGD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Preimplantation Genetics Diagnosis (PGD) Market Value (USD Million) By Region

Figure 23: Global Preimplantation Genetics Diagnosis (PGD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Preimplantation Genetics Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Preimplantation Genetics Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Preimplantation Genetics Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Preimplantation Genetics Diagnosis (PGD) Market Value (USD Million) By Region

Table 10: Global Preimplantation Genetics Diagnosis (PGD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Preimplantation Genetics Diagnosis (PGD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Preimplantation Genetics Diagnosis (PGD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Preimplantation Genetics Diagnosis (PGD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Natera, Inc. Basic Information And Sales Area

Table 33: Natera, Inc.. Products Portfolio

Table 34: PerkinElmer Basic Information And Sales Area

Table 35: PerkinElmer. Products Portfolio

Table 36: Illumina Basic Information And Sales Area

Table 37: Illumina. Products Portfolio

Table 38: F. Hoffmann-La Roche Basic Information And Sales Area

Table 39: F. Hoffmann-La Roche. Products Portfolio

Table 40: Thermo Fisher Scientific Basic Information And Sales Area

Table 41: Thermo Fisher Scientific. Products Portfolio

Table 42: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 43: Laboratory Corporation of America Holdings. Products Portfolio

Table 44: Agilent Technologies Basic Information And Sales Area

Table 45: Agilent Technologies. Products Portfolio

Table 46: Quest Diagnostics Incorporated Basic Information And Sales Area

Table 47: Quest Diagnostics Incorporated. Products Portfolio

Table 48: Cooper Surgical Basic Information And Sales Area

Table 49: Cooper Surgical. Products Portfolio

Table 50: Beijing Genomics Institute (BGI) Basic Information And Sales Area

Table 51: Beijing Genomics Institute (BGI). Products Portfolio

Table 52: Genea Limited Basic Information And Sales Area

Table 53: Genea Limited. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Preimplantation Genetics Diagnosis (PGD) Market Value (USD Million) By Region

Table 59: Global Preimplantation Genetics Diagnosis (PGD) Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Preimplantation Genetics Diagnosis (PGD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	27.40 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Natera, Inc.; PerkinElmer; Illumina; F. Hoffmann-La Roche; Thermo Fisher Scientific; Laboratory Corporation of America Holdings; Agilent Technologies; Quest Diagnostics Incorporated; Cooper Surgical; Beijing Genomics Institute (BGI); Genea Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in genetic sequencing technologies have improved the accuracy and efficiency of PGD procedures, making them more accessible to a wider range of patients.

Government initiatives and funding for genetic research have supported the development of new PGD technologies and treatments, driving market growth.

Restraints2 items

High costs associated with PGD procedures and limited insurance coverage have restricted access to these services, hindering market growth.

Stringent regulatory frameworks and ethical concerns surrounding genetic testing have slowed the adoption of PGD technologies in some regions.

Opportunities2 items

The increasing prevalence of genetic disorders and rising demand for personalized medicine have created new opportunities for PGD market players to develop targeted treatments and services.

Challenges2 items

Market Segmentation

Loading chart…

Preimplantation Genetics Diagnosis (PGD) Segmentation Breakdown12 items

Application

Hospitals

Clinics

Others

Types

Gender Selection

Chromosomal Abnormalities

Single Gene Disorders

HLA Typing

Aneuploidy

X-Linked Diseases

Others

Regional Insights

Loading chart…

Competitive Landscape

Abbott Laboratories: regional expansion

Natera, Inc.: innovation pipeline

PerkinElmer: premium pricing

Illumina: OEM tie-ups

F. Hoffmann-La Roche: local manufacturing

Thermo Fisher Scientific: vertical integration

Key Preimplantation Genetics Diagnosis (PGD) Companies12 items

Abbott Laboratories

Natera, Inc.

PerkinElmer

Illumina

F. Hoffmann-La Roche

Thermo Fisher Scientific

Laboratory Corporation of America Holdings

Agilent Technologies

Quest Diagnostics Incorporated

Cooper Surgical

Beijing Genomics Institute (BGI)

Genea Limited

Market Ecosystem

Technology providers — supply genetic testing products

System integrators — develop and implement PGD protocols

Distributors — deliver PGD products to clinical settings

Service providers — offer PGD testing and counseling services

End users — patients seeking genetic testing and counseling

Regulators — establish standards and approvals for PGD technologies

Data/analytics providers — support PGD data interpretation and analysis

Recent Industry Insights

Analyst Overview

Table of Contents